According to a recent article published in the journal Cancer, women with early breast cancer have significantly improved survival when treated in a hospital that treats a greater number of women with this stage of disease and/or in a hospital involved in research and teaching activities.

Lymph-node negative breast cancer refers to cancer that has not spread outside the breast. Overall cure rates for women diagnosed with lymph-node negative breast cancer are high following standard treatment approaches. However, a significant portion of these women experience a cancer recurrence and may ultimately succumb to their disease. Researchers have been focusing on cancer and patient characteristics that possibly define which women are at a higher risk of developing a recurrence. Findings may allow treatment strategies to be individualized and long-term outcomes improved.

One factor that appears associated with long-term survival is the institution at which a patient is treated. Several previous studies have indicated that patients often have improved outcomes if they receive treatment at an institution that treats a large volume of patients with their specific disease (high-volume) and/or are treated by a high-volume physician.

Researchers from Canada recently conducted a study to determine if an association exists between long-term outcomes and medical institutions at which women with lymph-node negative breast cancer are treated. This study included the review of outcomes of women treated at medical facilities that treated different volumes of patients with lymph-node negative breast cancer. Data from different types of medical facilities (i.e. teaching and research versus not) as also included. Overall, women treated at high-volume medical facilities and those treated at teaching or research facilities had significantly improved survival compared to women treated at low-volume hospitals and/or facilities not involved in research or teaching.

Recommended Articles

Image placeholder title

Ask the Experts About Circulating Tumor DNA in the Management of Cancer

Ask the Experts About Circulating Tumor DNA (ctDNA) in the Management of Cancer

Image placeholder title

Tisotumab Vedotin – Promising in Advanced Cervical Cancer

Novel precision cancer medicine promising for treatment of advanced ovarian cancer.

Image placeholder title

Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer

Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.

  • Death rate was increased 70% for women treated at low-volume medical facilities (25 or fewer new cases of lymph-node negative breast cancer per year) compared to those treated at high-volume medical facilities (100 or more new cases per year).
  • Death rate was increased 44% and 30%, respectively, for women treated at facilities that treated 25-49 new cases per year and 50-99 new cases per year.
  • Death rate was decreased by 30% in medical institutions involved in research, teaching, or those with onsite radiation facilities

The researchers concluded that women with node-negative breast cancer have significantly improved survival if treated in high-volume hospitals and/or hospitals involved in teaching, research, or those that have onsite radiation facilities. Patients diagnosed with lymph-node negative breast cancer may wish to ask their physician about patient-volume for their stage of disease at the treating facility, as well as the institution’s involvement in teaching and research and radiation facilities.

Reference: Hebert-Croteau N, Brisson J, Lemiaire J, et al. Investigating the correlation between hospital of primary treatment and survival of women with breast cancer. Cancer. 2005;104:1343-1348.

Related News:Test Helps Identify Risk of Recurrence in Node-Negative Breast Cancer

Copyright © 2018 CancerConnect. All Rights Reserved.